Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for an audio catch-up on the past week's major events in the global biopharma industry, as brought to you by Scrip's global team, in this mini podcast version of Five Must-Know Things. 

This episode includes the main news from around the biopharma world in the business week ended 18 December 2020. 

This week, we look at a big deal in immunology, a story of vaccine success, Japan’s vaccine environment, one big pharma firm’s challenges and opportunities, and a disappointment in rheumatoid arthritis.

Stories mentioned in this episode:

(Also see "AZ's Alexion Acquisition Looks Astute Bit Of Business" - Scrip, 13 Dec, 2020.)

(Also see "Pfizer Rose To The COVID-19 Challenge And The Stars Aligned" - Scrip, 11 Dec, 2020.)

(Also see "Pharma Power Japan Barely In COVID Vaccines Race. Why?" - Scrip, 16 Dec, 2020.)

(Also see "AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025" - Scrip, 14 Dec, 2020.)

(Also see "Gilead Gives Up On Galapagos's Filgotinib In RA" - Scrip, 16 Dec, 2020.)


These and all Informa Pharma Intelligence podcasts are available on SoundCloud, Apple Podcasts, TuneIn and Google Play and also via smart speakers - just make sure one of these providers is set up as your default for podcasts, and then ask for "Pharma Intelligence podcasts".


Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts